eXagen™ helps pharmaceutical companies advance their business and scientific objectives for clinical trials through rapid identification, development and licensing of small, optimized combinations of markers in support of pharmaceutical R&D or clinical trials.

Using proprietary technology, eXagen identifies the smallest marker sets (DNA or RNA) that are optimal for a defined purpose, in weeks rather than months. eXagen has completed more than 10 projects in various indications, proving the validity of our approach. We have consistently discovered sets with 3-5 markers, offering pharmaceutical organizations efficiency of implementation and economy of scale.

Our co-development and project-based work covers the full spectrum of testing, from "wet lab" specimen testing/data collection to validation, to final production and testing of the marker set in the desired assay format.

For more information about eXagen's capabilities in this area, please contact:
Public Relations at eXagen DIAGNOSTICS, Inc.™
PublicRelations@eXagen.com
866.392.4361